[Determination of epidermal growth factor (EGF) receptors in basal cell carcinomas, squamous cell carcinomas and melanomas].
We studied the binding of EGF receptors (EGF-R) in 19 basal cell carcinomas, 8 squamous cell carcinomas, and 9 malignant melanomas. Specific binding of EGF-R was detected in 10 of the basal cell carcinomas, and in all the 8 squamous cell carcinomas. None of the malignant melanomas showed EGF-R binding. A comparative study of the receptor status vs. clinical prognostic data, such as grading and clinical course, did not reveal any significant differences, whereas in ovarian carcinomas, the EGF receptor correlated with the prognosis.
Hagedorn
M
M
Hautklinik, Städtischen Klinik Darmstadt.
Vanscheidt
W
W
Strasser
W
W
Bauknecht
T
T
D014408:Biomarkers, Tumor / Q000032:analysis*; D002280:Basal Cell Carcinoma / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D066246:ErbB Receptors / Q000032:analysis*; D005500:Follow-Up Studies; D006801:Humans; D008545:Melanoma / Q000473:pathology*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000473:pathology*
D014408:Biomarkers, Tumor; D066246:ErbB Receptors
Bestimmung des "Epidermal Growth Factor" (EGF)-Rezeptors bei Basaliomen, Stachelzellkarzinomen und Melanomen.